<DOC>
	<DOC>NCT01046110</DOC>
	<brief_summary>This trial will be conducted in Africa, Asia, North America and South America. The aim of this clinical trial is to compare NN1250 (insulin degludec) with sitagliptin, as add-on to subject's own current oral antidiabetic (OAD) treatment, in subjects with type 2 diabetes inadequately controlled with 1-2 OADs (metformin, sulphonylurea, glinides or pioglitazone).</brief_summary>
	<brief_title>Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Type 2 diabetes (diagnosed clinically) for at least 6 months Ongoing treatment with 1 or 2 of the following OADs (metformin, insulin secretagogue (sulphonylurea or glinides) or pioglitazone) in any combination with unchanged dosing for at least 3 months prior to Visit 1 with the minimum doses stated: Metformin: alone or in combination (including fixed combination)1500 mg or maximum tolerated dose (at least 1000 mg daily) Insulin secretagogue (sulfonylurea or glinide): minimum half of the maximal daily dose according to local labelling Pioglitazone: minimum half of the maximal daily dose according to local labelling or maximum tolerated dose Body Mass Index (BMI) below or equal to 40.0 kg/m^2 HbA1c 7.511.0 % (both inclusive) by central laboratory analysis Use within the last 3 months prior to Visit 1 of: exenatide, liraglutide, rosiglitazone or acarbose Cardiovascular disease, within the last 6 months prior to Visit 1, defined as: stroke; decompensated heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least 180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg) Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during the last 12 months) or hypoglycaemic unawareness as judged by the Investigator or hospitalisation for diabetic ketoacidosis during the previous 6 months Pregnancy, breastfeeding, the intention of becoming pregnant or not using adequate Cancer and medical history hereof (except basal cell skin cancer or squamous cell skin cancer)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>